HEALIUS LIMITED (HLS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

HLS - HEALIUS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.75
Index: ASX200 | ASX300 | ALL-ORDS

Healius, formerly Primary Health Care, is an Australian provider of Pathology, Diagnostic and Day Hospital services. It has been listed since 1998.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.21

18 Apr
2024

0.005

OPEN

$1.19

0.41%

HIGH

$1.22

783,846

LOW

$1.18

TARGET
$1.554 28.4% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
HLS: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A - 0.1 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/09 - ex-div 6c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-60.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx1,706.9 M
Book Value Per Share xxxxxxxxxxxxxxx244.8
Net Operating Cash Flow xxxxxxxxxxxxxxx306.4 M
Net Profit Margin xxxxxxxxxxxxxxx-22.26 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-22.17 %
Return on Invested Capital xxxxxxxxxxxxxxx-11.72 %
Return on Assets xxxxxxxxxxxxxxx-9.76 %
Return on Equity xxxxxxxxxxxxxxx-22.17 %
Return on Total Capital xxxxxxxxxxxxxxx2.72 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx209.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx263 M
Long Term Debt xxxxxxxxxxxxxxx1,503 M
Total Debt xxxxxxxxxxxxxxx1,766 M
Goodwill - Gross xxxxxxxxxxxxxxx1,898 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx115 M
Price To Book Value xxxxxxxxxxxxxxx1.20

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx76.1 M
Capex % of Sales xxxxxxxxxxxxxxx4.46 %
Cost of Goods Sold xxxxxxxxxxxxxxx1,365 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx247 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx7 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.2

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

28/02/2024

5

Underweight

$1.00

-17.36%

Healius' revenue was in line with expectation and underlying earnings were in line with the guidance range, Morgan Stanley notes. Managament pointed out the sector is experiencing low growth for GP volumes to which Healius has greater exposure.

Pathology revenue was in line but Healius has again written down the value of pathology business, by -$603m, in addition to write-down of -$350m made in FY23.

FY24 earnings guidance of $70-80m was reiterated, which was initially guided to a range of $95-105m, the broker notes.

Underweight. The target is reduced to $1.00 from $1.30 tafter the broker allows for lower core pathology volume growth and structural cost challenges in the business. Industry view: In-Line.

FORECAST
Morgan Stanley forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.00 cents.
Morgan Stanley forecasts a full year FY25 dividend of 1.90 cents and EPS of 4.00 cents.

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

HLS STOCK CHART